INVEGA TRINZA Drug Patent Profile

When do Invega Trinza patents expire, and what generic alternatives are available?

Invega Trinza is a drug marketed by Janssen Pharms and is included in one NDA. There is one patent protecting this drug and three Paragraph IV challenges.

The generic ingredient in INVEGA TRINZA is paliperidone palmitate. There is one drug master file entry for this compound. Three suppliers are listed for this compound. Additional details are available on the paliperidone palmitate profile page.

DrugPatentWatch^® Generic Entry Outlook for Invega Trinza

There have been four patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are five tentative approvals for the generic drug (paliperidone palmitate), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for INVEGA TRINZA

US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	65
Patent Applications:	313
Drug Prices:	Drug price information for INVEGA TRINZA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for INVEGA TRINZA
What excipients (inactive ingredients) are in INVEGA TRINZA?	INVEGA TRINZA excipients list
DailyMed Link:	INVEGA TRINZA at DailyMed

See drug prices for INVEGA TRINZA

Pharmacology for INVEGA TRINZA

Drug Class

Atypical Antipsychotic

Paragraph IV (Patent) Challenges for INVEGA TRINZA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
INVEGA TRINZA	Extended-release Injectable Suspension	paliperidone palmitate	273 mg/0.875 mL and 410 mg/1.315 mL	207946	1	2021-07-14
INVEGA TRINZA	Extended-release Injectable Suspension	paliperidone palmitate	819 mg/2.625 mL	207946	1	2021-04-30
INVEGA TRINZA	Extended-release Injectable Suspension	paliperidone palmitate	546 mg/1.75 mL	207946	1	2020-06-24

US Patents and Regulatory Information for INVEGA TRINZA

INVEGA TRINZA is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Pharms	INVEGA TRINZA	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207946-001	May 18, 2015		RX	Yes	Yes	10,143,693
Janssen Pharms	INVEGA TRINZA	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207946-004	May 18, 2015		RX	Yes	Yes	10,143,693
Janssen Pharms	INVEGA TRINZA	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207946-002	May 18, 2015		RX	Yes	Yes	10,143,693

International Patents for INVEGA TRINZA

When does loss-of-exclusivity occur for INVEGA TRINZA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Finland

Hong Kong

Hungary

Israel

Japan

Lithuania

Moldova, Republic of

Morocco

New Zealand

Poland

Portugal

San Marino

Serbia

Slovenia

South Korea

Spain

Taiwan

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering INVEGA TRINZA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2016244801
Australia	2020239611
Australia	2022221405

Supplementary Protection Certificates for INVEGA TRINZA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0368388	07C0044	France		PRODUCT NAME: PALIPERIDONE; REGISTRATION NO/DATE IN FRANCE: EU/1/07/395/01 DU 20070626; REGISTRATION NO/DATE AT EEC: EU/1/07/395/01 DU 20070625
0368388	SPC/GB07/065	United Kingdom		PRODUCT NAME: PALIPERIDONE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/07/395/001 20070625; UK EU/1/07/395/002 20070625; UK EU/1/07/395/003 20070625; UK EU/1/07/395/004 20070625; UK EU/1/07/395/005 20070625; UK EU/1/07/395/006 20070625; UK EU/1/07/395/007 20070625; UK EU/1/07/395/008 20070625; UK EU/1/07/395/009 20070625; UK EU/1/07/395/010 20070625; UK EU/1/07/395/011 20070625; UK EU/1/07/395/012 20070625; UK EU/1/07/395/013 20070625; UK EU/1/07/395/014 20070625; UK EU/1/07/395/015 20070625; UK EU/1/07/395/016 20070625; UK EU/1/07/395/017 20070625; UK EU/1/07/395/018 20070625; UK EU/1/07/395/019 20070625; UK EU/1/07/395/020 20070625; UK EU/1/07/395/021
0904081	C300491	Netherlands		PRODUCT NAME: PALIPERIDONPALMITAAT; REGISTRATION NO/DATE: EU/1/11/672/001-006 20110304

INVEGA TRINZA Market Dynamics, Patent Protection, Financial Trajectory, and Generic Risk

Last updated: September 30, 2026

INVEGA TRINZA is a three-month long-acting injectable formulation of paliperidone palmitate marketed by Janssen Pharmaceuticals, a Johnson & Johnson company. Its commercial value comes from extending treatment intervals beyond INVEGA SUSTENNA, which is administered monthly. The product is positioned for adults with schizophrenia who have been adequately treated with the one-month formulation.

INVEGA TRINZA benefits from high treatment persistence, limited direct competition in the three-month schizophrenia injection segment, and manufacturing complexity. Its principal risks are exposure to the broader paliperidone franchise, future generic challenges to the long-acting injectable formulation, pricing pressure from competing atypical antipsychotics, and the absence of separately reported product revenue.

What is INVEGA TRINZA and how does it work?

INVEGA TRINZA contains paliperidone palmitate, the palmitate ester prodrug of paliperidone. It is administered by intramuscular injection once every three months after stabilization with monthly paliperidone palmitate.

The product uses nanocrystal technology to create a depot formulation that slowly releases paliperidone after injection. Its approved indication is the treatment of schizophrenia in adults who have been adequately treated with INVEGA SUSTENNA for at least four months, with the last two doses at the same strength.

Product	Active ingredient	Administration interval	Manufacturer
INVEGA SUSTENNA	Paliperidone palmitate	Monthly	Janssen
INVEGA TRINZA	Paliperidone palmitate	Every three months	Janssen
INVEGA HAFYERA	Paliperidone palmitate	Every six months	Janssen
ABILIFY MAINTENA	Aripiprazole	Monthly or longer depending on regimen	Otsuka
ARISTADA	Aripiprazole lauroxil	Every four to eight weeks	Alkermes
UZEDY	Risperidone	Monthly or every two months	Teva

INVEGA TRINZA is not interchangeable with oral paliperidone or with other long-acting injectable antipsychotics on a dose-for-dose basis. Its prescribing pathway requires prior stabilization, which limits immediate treatment initiation but reduces conversion risk after patients enter the paliperidone franchise. [1]

What FDA regulatory approvals and exclusivity apply to INVEGA TRINZA?

The FDA approved INVEGA TRINZA in May 2015. The product was the first three-month paliperidone palmitate injection approved in the United States. FDA approval was based on a maintenance-treatment strategy in adults with schizophrenia who were already stabilized on INVEGA SUSTENNA. [2]

The product is regulated as a small-molecule drug under the Federal Food, Drug, and Cosmetic Act. It is not a biologic and does not receive the 12-year biologic exclusivity period under the Public Health Service Act.

The principal regulatory protections have been:

• New drug application protection associated with the original approval.
• Patent protection covering paliperidone palmitate formulations, dosing schedules, and administration methods.
• Potential pediatric exclusivity, if awarded for qualifying studies.
• Patent-term adjustment or extension for qualifying patents, subject to statutory limits.

The most commercially important protection is patent coverage rather than regulatory exclusivity. INVEGA TRINZA’s dosing interval and depot formulation create a more difficult generic development pathway than an oral tablet.

What patents protect INVEGA TRINZA?

Public patent records identify a portfolio covering the paliperidone palmitate depot formulation and the three-month dosing regimen. The most frequently cited U.S. patents associated with INVEGA TRINZA include the following:

Patent	General subject matter	Reported nominal expiration
U.S. Patent No. 9,439,906	Long-acting paliperidone palmitate formulation and related use	2031
U.S. Patent No. 9,452,134	Paliperidone palmitate dosing and treatment methods	2031
Related continuation and formulation patents	Depot composition, particle characteristics, dosing, and administration	Early-to-mid 2030s, depending on patent

The exact Orange Book position must be assessed patent by patent because patent listings, delistings, terminal disclaimers, pediatric extensions, patent-term adjustments, and litigation outcomes can alter the effective barrier to launch. Janssen has historically relied on layered protection rather than a single patent.

What formulations are protected by INVEGA TRINZA patents?

The relevant patent estate can cover:

• Paliperidone palmitate in an aqueous injectable suspension.
• Particle-size and crystalline-form characteristics.
• Long-acting release profiles.
• Dosage strengths administered at three-month intervals.
• Conversion from monthly paliperidone palmitate to the three-month formulation.
• Maintenance treatment of schizophrenia using extended dosing intervals.
• Manufacturing and suspension properties that support syringeability and dose uniformity.

Formulation claims are commercially important because a generic applicant must reproduce a clinically equivalent release profile without infringing valid claims. A conventional injectable suspension may not be sufficient if it fails to match the reference product’s pharmacokinetic profile or injection performance.

What is the Orange Book status of INVEGA TRINZA?

INVEGA TRINZA is an FDA-approved prescription drug with Orange Book-listed patents associated with its approved drug product. The Orange Book is the primary U.S. source for determining listed patents, patent expiration information, and whether a generic applicant must make a Paragraph IV certification against an asserted patent. [3]

The commercial effect of an Orange Book listing depends on:

1. Whether a patent remains listed at the time of ANDA filing.
2. Whether the patent claims the drug, formulation, or approved method of use.
3. Whether the generic applicant files a Paragraph IV certification.
4. Whether Janssen files a patent-infringement action within 45 days.
5. Whether litigation produces a stay, settlement, invalidity finding, or noninfringement judgment.

A patent expiration shown in the Orange Book does not automatically establish the earliest lawful generic launch date. The result can be affected by litigation, settlement terms, pediatric exclusivity, forfeiture rules, and non-Orange Book patents.

When does INVEGA TRINZA lose exclusivity?

The principal U.S. patent barriers publicly associated with INVEGA TRINZA extend into approximately 2031, with related continuation or formulation rights potentially extending beyond that date. A practical generic-entry assessment should therefore use a range rather than a single cliff date.

Period	Commercial implication
2025-2027	Continued protection from the core three-month formulation and dosing estate; limited direct generic threat expected absent a successful challenge
2028-2030	Greater probability of ANDA filings, Paragraph IV certifications, and settlement activity
Around 2031	Potential core patent expiry window for major listed patents
2031 onward	Entry depends on remaining formulation, method-of-use, manufacturing, and continuation patents
Early-to-mid 2030s	Possible residual protection from later-filed or continuation patents, subject to validity and enforceability

INVEGA TRINZA is likely to face a staggered entry pattern rather than an immediate broad erosion event. Generic competition may initially target selected dosage strengths or use carve-outs for patented methods.

Which companies are challenging INVEGA TRINZA?

Publicly available information has not established a broad, settled field of commercial generic entrants for INVEGA TRINZA comparable to the generic activity surrounding older oral antipsychotics. The absence of a widely disclosed launch does not exclude confidential ANDA filings or Paragraph IV certifications.

Potential challengers would include generic companies with capabilities in:

• Sterile injectable manufacturing.
• Nanocrystal or suspension formulation.
• Complex pharmacokinetic development.
• Microsampling and depot-release bioequivalence studies.
• Controlled-substance and high-potency manufacturing operations.

Teva, Sandoz, Viatris, Amneal, Hikma, and specialty injectable manufacturers have the technical scale to evaluate such an opportunity, but public evidence of a successful U.S. INVEGA TRINZA launch remains limited through the latest broadly available company disclosures.

What patent litigation affects INVEGA TRINZA?

The relevant litigation risk is concentrated in three areas:

Paragraph IV litigation

An ANDA applicant can certify that listed patents are invalid, unenforceable, or not infringed. Janssen can then file suit within 45 days, triggering a statutory stay of FDA approval for up to 30 months, subject to court decisions and statutory exceptions.

Method-of-use litigation

A generic applicant may seek approval with a Section viii statement that omits a patented method of use. That strategy can narrow the product label and reduce direct infringement exposure. It may also limit the commercial scope of the generic launch.

Formulation and manufacturing litigation

Janssen may assert claims directed to particle size, suspension characteristics, drug concentration, delivery performance, or manufacturing steps. These claims can remain relevant even if a generic applicant avoids a method-of-use patent.

No definitive, publicly reported settlement framework has established a universal generic launch date for INVEGA TRINZA. A settlement would be material because it could authorize an entry date before the full expiration of all asserted patents.

How strong is the INVEGA TRINZA patent estate?

The patent estate is commercially strong but not unassailable.

Strengths

• The product has a differentiated three-month dosing schedule.
• The formulation is technically complex.
• The approved regimen depends on conversion from INVEGA SUSTENNA.
• Manufacturing and release characteristics may be difficult to replicate.
• Janssen can combine formulation, dosing, method-of-use, and process claims.
• The product benefits from a broader franchise that includes SUSTENNA and HAFYERA.

Weaknesses

• Paliperidone palmitate is a known active pharmaceutical ingredient.
• Generic developers can challenge obviousness, written description, enablement, and claim-scope issues.
• Method-of-use claims may be vulnerable to label carve-outs.
• Some formulation claims may face prior-art challenges.
• The product is a small molecule, so it lacks biologic-style interchangeability barriers.
• Once one technically credible generic enters, price pressure may accelerate.

The strongest protection is likely the combination of formulation complexity and the need to demonstrate an equivalent long-acting release profile. Patent validity alone does not determine commercial durability; manufacturing capability and regulatory substitutability are also important.

What is the financial trajectory of INVEGA TRINZA?

Johnson & Johnson does not generally disclose INVEGA TRINZA revenue as a separate line item. It reports INVEGA within its Innovative Medicine portfolio, so public financial data usually combine INVEGA TRINZA, INVEGA SUSTENNA, INVEGA HAFYERA, and potentially related products.

Johnson & Johnson reported global INVEGA franchise sales of approximately $4.1 billion in 2023, up from approximately $3.8 billion in 2022. The reported growth reflected demand for long-acting injectable paliperidone products and continued franchise expansion. [4]

Financial factor	Effect on INVEGA TRINZA
Long-acting injectable adoption	Supports volume growth and recurring revenue
Three-month dosing	Improves convenience and may support persistence
Conversion from SUSTENNA	Creates an internal franchise migration pathway
HAFYERA launch	Can shift high-persistence patients to a six-month product
Pricing and payer control	Limits net-price expansion
Generic entry	Creates the largest future erosion risk
Product-level disclosure	Prevents precise standalone revenue modeling

INVEGA TRINZA’s financial trajectory is best understood as a portfolio migration model. Janssen can retain patients within the paliperidone franchise as they move from monthly SUSTENNA to three-month TRINZA and, where clinically appropriate, to six-month HAFYERA. That reduces immediate franchise loss but can shift revenue among products.

The product’s economics are favorable because a three-month injection can reduce administration frequency while maintaining branded pricing. Revenue growth depends more on patient conversion and persistence than on new diagnosis alone.

How does INVEGA TRINZA compare with competing long-acting antipsychotics?

Product	Molecule	Longest labeled interval	Competitive position
INVEGA TRINZA	Paliperidone palmitate	Three months	Established three-month paliperidone option
INVEGA HAFYERA	Paliperidone palmitate	Six months	Longer-interval extension of the same franchise
ARISTADA	Aripiprazole lauroxil	Eight weeks	Flexible dosing; requires oral overlap or initiation strategy
ABILIFY ASIMTUFII	Aripiprazole	Two months	Long-acting aripiprazole option
UZEDY	Risperidone	Two months	Extended-release risperidone with shorter interval than TRINZA
PERSERIS	Risperidone	Monthly	Subcutaneous delivery and no oral supplementation in labeled initiation

INVEGA TRINZA’s primary competitive advantage is interval length relative to most alternatives. Its limitations include the requirement for prior SUSTENNA stabilization, a schizophrenia-only positioning, injection-site considerations, and exposure to the emerging six-month HAFYERA product.

What generic entry risks exist for INVEGA TRINZA?

The most probable generic launch scenarios are:

1. Delayed entry after expiration or settlement of the core formulation patents.
2. A first-to-file Paragraph IV launch by one technically capable injectable manufacturer.
3. A limited label launch using method-of-use carve-outs.
4. Multiple entrants after the first generic demonstrates regulatory and manufacturing feasibility.
5. Initial discounting below the branded net price, followed by larger erosion after broad substitution.

Generic erosion may be slower than for oral paliperidone because:

• The product requires sterile suspension manufacturing.
• Bioequivalence is more complex.
• The injection must reproduce long-duration exposure.
• Health systems may require conversion protocols.
• Physicians may be reluctant to switch stable patients.
• Payer substitution rules may differ from those for oral generics.

The risk increases materially if a generic applicant obtains an ANDA approval with a commercially usable label and demonstrates reliable supply. The first approved generic could gain disproportionate share because of the limited number of competitors capable of producing the product.

What licensing deals and manufacturing barriers affect INVEGA TRINZA?

The core product is associated with Janssen’s paliperidone franchise and does not depend on a publicly prominent external commercialization license. The important commercial asset is the integrated franchise strategy linking INVEGA SUSTENNA, INVEGA TRINZA, and INVEGA HAFYERA.

Manufacturing barriers include:

• Production of uniform paliperidone palmitate particles.
• Control of suspension viscosity and settling.
• Sterile filling in prefilled syringes.
• Consistent dose delivery across strengths.
• Long-term stability testing.
• Validated release specifications.
• Scale-up without altering pharmacokinetic performance.

These barriers support pricing durability but do not eliminate generic risk. A capable injectable manufacturer can convert technical barriers into a competitive advantage once the formulation and regulatory pathway are established.

What revenue exposure does Johnson & Johnson face?

The exposure is substantial at the franchise level but cannot be isolated precisely for INVEGA TRINZA because Johnson & Johnson reports combined INVEGA revenue.

The principal downside drivers are:

• Loss of share to generic paliperidone products.
• Internal cannibalization by HAFYERA.
• Competing long-acting aripiprazole products.
• Payer pressure on branded injectable antipsychotics.
• Reduced treatment initiation in institutional and public-sector channels.
• Patent litigation outcomes that accelerate entry.

The principal offsets are:

• Continued migration from oral therapy to long-acting injectables.
• Conversion from SUSTENNA to TRINZA.
• Patient retention within the paliperidone franchise.
• Expansion of HAFYERA in patients suitable for six-month dosing.
• High clinical and operational costs associated with switching stable patients.

Key Takeaways

• INVEGA TRINZA is Janssen’s three-month paliperidone palmitate injection for adults with schizophrenia stabilized on INVEGA SUSTENNA.
• Its value is based on dosing convenience, treatment persistence, and technical formulation complexity.
• Johnson & Johnson reports INVEGA revenue at the franchise level, not separately for TRINZA.
• The INVEGA franchise generated approximately $4.1 billion in global sales in 2023, according to Johnson & Johnson’s annual report.
• Core U.S. patent protection associated with TRINZA extends into approximately 2031, with related patents potentially extending beyond that date.
• No broadly established U.S. generic launch has materially disrupted INVEGA TRINZA through the latest publicly available disclosures.
• Generic risk is likely to emerge through Paragraph IV challenges and could produce staggered entry rather than a single immediate cliff.
• HAFYERA protects the broader franchise while creating internal substitution risk for TRINZA.
• The main manufacturing barriers are sterile suspension production, particle control, dose uniformity, and long-duration pharmacokinetic equivalence.
• The most important commercial variable is the timing and structure of the first successful generic launch.

FAQs

Is INVEGA TRINZA a biologic?

No. INVEGA TRINZA is a small-molecule drug containing paliperidone palmitate. It does not receive the 12-year biologic exclusivity period applicable to reference biologics.

Can patients switch directly from INVEGA SUSTENNA to INVEGA TRINZA?

Patients must first be adequately treated with INVEGA SUSTENNA, generally for at least four months, with the last two doses at the same strength before conversion to the corresponding three-month regimen. [1]

Does INVEGA TRINZA have biosimilar competition?

No. Biosimilars apply to biologic products. Any future competitor would be regulated as a generic or complex injectable equivalent, not as a biosimilar.

Will INVEGA HAFYERA reduce INVEGA TRINZA sales?

It can reduce TRINZA volume through internal migration, but it may preserve patients within Janssen’s paliperidone franchise. The net effect depends on relative pricing, eligibility, physician adoption, and payer coverage.

What is the main barrier to an INVEGA TRINZA generic?

The primary barrier is reproducing the reference product’s long-acting injectable formulation and pharmacokinetic profile at commercial scale while satisfying FDA equivalence requirements and avoiding valid formulation or method-of-use patents.

References

1. U.S. Food and Drug Administration. (2024). INVEGA TRINZA prescribing information. Janssen Pharmaceuticals, Inc. https://www.accessdata.fda.gov
2. U.S. Food and Drug Administration. (2015). FDA approves three-month formulation of INVEGA for schizophrenia. https://www.fda.gov
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
4. Johnson & Johnson. (2024). 2023 annual report. https://www.jnj.com/investor-relations/financials/annual-reports
5. U.S. Patent and Trademark Office. (2016). U.S. Patent No. 9,439,906. https://patents.google.com
6. U.S. Patent and Trademark Office. (2016). U.S. Patent No. 9,452,134. https://patents.google.com